Mrs Bindi Chudgar is one of the most distinguished women in the corporate world.
Since inception, Mrs Chudgar's entrepreneurial intellect has ensured that Lambda
grows both organically and inorganically to become a truly global CRO. Over the
years, her progressive vision and values have helped Lambda create a niche to
stand apart from the rest in the CRO industry. Meticulous by nature, she
overlooks Lambda’s Corporate M&A, Strategy, Finance & Human Resources embracing
the best of contemporary and conventional ideologies which are the best fit for
the organization globally.
Mrs Chudgar’s keenness on high-quality standards is best reflected in Lambda's exceptional regulatory track record. The organisation's various facilities across the world have undergone successful accreditations by some of the world’s topmost regulatory agencies. It is her visionary genius and strong-willed determination that helps Lambda transcend geographical boundaries to excel in the world's most promising pharmaceutical markets, besides continually augmenting and diversifying its service portfolio and expertise.
Mrs Chudgar has always been a people's person. She believes in building an engaging and empowering work culture which are the foundation and key drivers for building a strong and successful organisation.
She is determined to continue raising the bar for the development and commercialization of new medical therapies worldwide, through Lambda.
Dr Tausif brings with him a rich experience of more than 24 years in the Clinical
During his tenure with Ranbaxy and subsequently Sun Pharmaceuticals, he played a
pivotal role in the success of the company’s multiple marketing authorizations in
the US, EU and RoW markets. He was also in parallel heading their Clinical
Operations in Eastern Europe.
He has numerous publications and academic accreditations to his credit and has successfully faced multiple Regulatory Audits across the world in his illustrious career.
His last assignment was as Vice President-Sun Pharmaceuticals heading their Clinical Pharmacology and Pharmacokinetic division globally and played a pivotal role in advancing their New Drug Development portfolio with his varied experience.
Dr. Kammili possesses more than 22 years of combined industry experience, in Hospital and Clinical Research domains in the Health Care Industry. Dr. Kammili is ICH-GCP certified, well versed in Indian and International Regulatory guidelines applicable to Bioequivalence and Bioavailability studies, Phase 1, Phase II-IV Trials, Medical Writing, Data Management, Pharmacovigilance and Medical Imaging.
Presently, Dr. Kammili is a member on the Board of Directors and Global Head–Business Development for International (US / EU / Turkey / S.E. Asia / ROW and Emerging) markets and Indian domestic market.
He is actively involved in all M&A activities of Lambda group of companies and as a successful P&L executive, has built and managed teams to deliver stretched goals with high profitability by creating improved systems, processes and synergies within the organizations to build efficiencies, credibility and trust among the stakeholders.
Apart from the Clinical Research Domain, Dr. Kammili is also a trained Intensivist, having assisted in various Interventional Cardiac emergency procedures like Primary Angioplasties, Coronary Angiograms, and Thrombolytic therapies.
He is also a certified Basic Life Support (BLS) and Advanced Cardiac Life Support (ACLS) provider by the American Heart Association.
Dr. Marthak has more than 35 years of experience in the field of clinical research. Dr. Marthak is awarded with an MD in Medicine from Dr. Grant Medical College and also possesses a Business Management degree. Dr. Marthak has vast experience in Phase I to Phase-IV clinical trials. He pioneered Phase I studies in India during his 13 year stint with Novartis in early 80s.
He was President – Association of Medical Advisors of Pharmaceutical Industry and an Executive Committee Member – International Federation of Association of Pharmaceutical Physicians as well as a Board Member for designing the modules for Academy of Clinical Research, Chief organizer of the International conference of Clinical Research held by CII-New Delhi in the year 2002 and a member of the Faculty for Pharmaceutical medicine – University of London, Fellow member – American College of Chest Physician, Fellow member – Royal Society of Medicine , London and Fellow of American College of Clinical Pharmacology, USA. Dr. Marthak is actively involved with regulatory authorities like US FDA, UK MHRA, China SFDA, South Africa MCC, MHCW and India – DCGI.
He is Co- chairman Medical Committee IDMA and active member of Pharmaceutical Committee of CII. He is a Chairman of an Independent Ethics Committee- ISBEC. He has published many articles in International and National reputed journals.
Dr. Kale has 27 years of immense experience in the analytical and bioanalytical domain. Dr. Kale is awarded with a Ph.D. (Chemistry) and also possess an MBA degree. He has numerous publications to his credit. He has been with Lambda for over 19 years. Prior to Lambda he was associated with SGS India Ltd. Presently, Dr. Kale is functioning as a Senior Vice President – BE Operations with Lambda Therapeutic Research and is responsible for the technical and administrative functions of the BE unit located at Ahmedabad, Mehsana and Mumbai, India. He is also responsible for bioanalytical laboratory at Toronto, Canada. Dr. Kale has faced several regulatory audits and inspections from leading regulatory bodies including but not limited to DCGI, USFDA, ANVISA, Health Canada, UK MHRA, Turkey MoH, WHO.
Mr. Chamberlain joined Novum in 2012 to lead the company’s strategic direction, operations and business management. Prior to joining Novum, Mr. Chamberlain was an executive in the media industry, most recently president of Pittsburgh’s leading media company, the Pittsburgh Post-Gazette. Previously, Mr. Chamberlain worked in executive, operational, strategic planning and business development roles at The New York Times and the Journal Register Company. Earlier in his career, Mr. Chamberlain was in the economic development field at a nongovernmental organization in Washington, D.C., where he conducted international development policy and program work. Mr. Chamberlain has served on numerous non-profit boards that focus on human services, education, and economic development.
Mr. Chamberlain holds an MBA from New York University and a BA in English literature from Colby College in Maine.
Dr. Gallicano brings more than 30 years of pharmaceutical experience to Novum. He has a background in pharmacokinetics, biopharmaceutics, biostatistics, bioanalytics and clinical trial design. He has previously served as scientific director for CroMedica Prime/Prime Trials, vice president of Research and Development and director of Pharmacokinetics for Axelson Biopharma Research, and director of Biopharmaceutics for Watson Laboratories. In his current position, he is responsible for leading a team of scientists and statisticians in developing protocols, analyzing data and generating high-quality final study reports for clinical research studies performed by Novum.
Dr. Gallicano earned a PhD in chemistry from the University of British Columbia.